Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:50 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study of M4344 in Combination With Niraparib
NCT04655183 · EMD Serono Research & Development Institute, Inc. · PHASE1/PHASE2 · withdrawn · last registry update 2021-06-30 · Breast cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Trial withdrawn based on portfolio prioritization; oral ATRi M1774 in combination with niraparib is under investigation in DDRiver Solid Tumor 301” | – | Registry record, EMD Serono Research & Development Institute, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PARP2 in breast cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-03-22Results posted on the registry: AstraZeneca, Olaparib Continuous (28-Day cycle) 300 mg BD. + Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle). (NCT03330847)
- 2021-12-08Results posted on the registry: AstraZeneca, Olaparib + Placebo (NCT02032823)
- 2020-07-22Results posted on the registry: National Cancer Institute (NCI), Cediranib Maleate + Olaparib (NCT01116648)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision